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ABSTRACT
Objective:  The prevalence of asthma in Italy is estimated to be around 4%; it affects 
approximately 2,000,000 citizens, and up to 80–90% of patients have mild-to-moderate 
asthma. Despite the clinical relevance of mild-to-moderate asthma, longitudinal observational 
data are very limited, including data on disease progression (worsening vs. improvement), 
the response to treatment, and prognosis. Studies are needed to develop long-term, 
observational, real-life research in large cohorts. The primary outcomes of this study will be 
based on prospective observation and the epidemiological evolution of mild and moderate 
asthma. Secondary outcomes will include patient-reported outcomes, treatments over time, 
disease-related functional and inflammatory patterns, and environmental and life-style 
influences.
Methods: This study, called the Mild/Moderate Asthma Network of Italy (MANI), is a research 
initiative launched by the Italian Respiratory Society and the Italian Society of Allergology, 
Asthma and Clinical Immunology. MANI is a cluster-based, real world, cross-sectional, 
prospective, observational cohort study that includes 20,000 patients with mild-to-moderate 
asthma. (ClinicalTrials.gov Identifier: NCT04796844).
Results and conclusion:  Despite advances in asthma care, several research gaps remain to 
be addressed through clinical research. This study will add important new knowledge about 
long-term disease history, the transferability of clinical research results to daily practice, the 
efficacy of currently recommended strategies, and their impact on the burden and evolution 
of the disease.
Abbreviations: MANI: Mild/Moderate Asthma Network of Italy; SANI: Severe Asthma Network 
Italy; GINA: Global Initiative for Asthma; SABA: short acting β2-agonists; ICS: inhaled 
corticosteroids; CRF: Case Report Form
Introduction
Describing the natural history of asthma is challeng-
ing for several reasons. First, data sources are often 
questionable; in fact, information mainly comes from 
studies on patients with predominantly severe or 
difficult-to-treat asthma rather than studies on 
patients with mild or moderate asthma (1). Moreover, 
data retrieved from hospitals, prescription databases, 
and mortality records are often incomplete. Studies 
on general population cohorts can be criticized for 
their uncertain diagnoses and poor definitions of the 
participants. Furthermore, studies do not always 
include clinically important variables, such as lung 
function, daily symptoms, and biomarkers. The het-
erogeneity of airway diseases grouped under the 
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“asthma” label is a reflection of the different pathways 
involved and the specific signs of disease progression, 
including lung function decline, remission, reoccur-
rence, morbidity, and mortality (2,3). Several studies 
have identified disease-related factors that could pre-
dict disease progression, including long-standing dis-
ease, severe symptoms, frequent exacerbations, 
smoking, exposure to allergens/pollutants and occu-
pational agents, chronic mucus hypersecretion, and 
high levels of airway hyperreactivity, IgE, and eosin-
ophils (4). However, other factors can influence dis-
ease evolution, like the drugs administered (short 
acting β2-agonists [SABA], controllers, oral cortico-
steroids, etc.), the dosing schedules (symptom-driven 
or continuous), and the drug administration tool 
(e.g., manual devices, smart inhalers, digital inter-
faces), in addition to the individual’s biological profile 
(comorbidities, concomitant disorders, inflammatory 
pattern) and sociodemographic profile (education, 
income, etc.). Furthermore, an over-reliance on 
inhaled SABAs increases the risk of asthma-related 
mortality (5). Although asthma-related mortality has 
been reduced substantially over the last few decades 
in most countries, it remains a concern, even among 
patients with mild asthma. It has become clear that 
some current clinical outcomes and behaviors in fac-
ing mild/moderate asthma need to be improved. The 
knowledge that morbidity was greater than previously 
appreciated among patients considered to have mild 
asthma has given rise to a document called the 
Global Initiative for Asthma (GINA) (6). This initia-
tive recommended the use of inhaled corticosteroids 
(ICS)/rapid-onset β2-agonists, in preference to SABA 
alone, as a medication to alleviate symptoms in all 
patients with asthma (7). Although it has been shown 
that even low doses of ICS reduced the risks of severe 
asthma exacerbations and asthma-related death, the 
use of oral steroids in non-severe asthma was asso-
ciated with substantial expense and comorbidities 
(8,9). Finally, albeit disease control is the goal of 
asthma management, severe exacerbations in mild 
asthma represent 30–40% of asthma exacerbations 
that require emergency consultations (10,11). 
Therefore, we need to improve the current under-
standing of the biology and pathophysiology of mild/
moderate asthma by identifying a number of distinct 
phenotypes, similar to the approach previously taken 
for investigating severe asthma (12–14).
The prevalence of asthma in Italy is estimated to 
be around 4%; it affects approximately 2,000,000 cit-
izens (15). Based on the minimum treatment needed 
to achieve asthma control, epidemiological studies 
have estimated that, among all patients with asthma, 
50–75% have mild asthma, 15–45% have moderate 
asthma, and 5–10% have severe asthma. The individ-
ual burden of the pathology is strictly related to the 
level of control and the severity. However, the burden 
on the social and welfare systems (number of 
events × number of patients) due to mild and mod-
erate asthma is not lower than that due to severe 
asthma. Indeed, if severe asthma requires more than 
50% of the available resources, the remaining 50% 
are used for managing the milder forms of asthma. 
This long-term study (MANI) aims to observe a large 
patient population to provide an unparalleled source 
of data for defining the most appropriate management 
measures.
Methods
This study is a research initiative launched by the 
Italian Respiratory Society and the Italian Society 
of Allergology, Asthma and Clinical Immunology 
which have set up an intersocieties scientific 
committee.
The primary outcome of MANI will be the epide-
miological evolution of mild and moderate asthma 
(disease severity, according to GINA), based on pro-
spective observation.
The following items will be explored as secondary 
outcomes:
• Real-life assessments of asthma control over 
time
• Exacerbation rate over time
• Patient-reported outcomes (e.g., quality of 
life, patient engagement, disease awareness) 
from groups treated with different drugs and 
schedules
• Burden of oral corticosteroids in mild and 
moderate asthma
• SABA use in mild and moderate asthma
• Influence of infections and vaccinations on dis-
ease outcomes and progression
• Influence of upper airway disease on disease 
outcomes and progression
• Impact of inhalation techniques and smart 
inhalers on disease outcomes and progression
• Environmental exposure influences on disease 
outcome and progression
• Evolution of inflammatory patterns over time 
and their relationships to disease outcomes and 
progression
• Role of smoking and life style in lung function 
and disease progression
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• Patient-reported outcomes over time
• Patient awareness and engagement in mild and 
moderate asthma
• Impact of digital therapy on disease manage-
ment and outcomes
• Direct, indirect, and intangible costs of mild 
and moderate asthma
• Cost-efficiency of mild/moderate asthma treat-
ments and management plans
• Sociodemographic issues related to disease pro-
gression and burden
MANI is a cluster-based, real world, cross-sectional, 
prospective, observational cohort study. A non-probability 
sample will include a population of male and female 
adult patients (18–80 years old) with a diagnosis of 
mild-to-moderate asthma, defined according to GINA 
2020. Patients will be enrolled at 200 centers of pulm-
onology and allergology distributed throughout the 
national territory. We will enroll consecutive patients 
with asthma that are referred to the outpatient clinics 
of the recruiting centers. Exclusion criteria are: patients 
with severe asthma, according to the International 
European Respiratory Society/American Thoracic Society 
guidelines on the definition, evaluation, and treatment 
of severe asthma (15); patients with interstitial lung 
diseases, pulmonary neoplasms, or current lung infec-
tions; and patients with immunological disorders that 
require immunosuppressants or continuous treatment 
with oral steroids. To represent real-world Italian patients 
with mild or moderate asthma, the inclusion criteria 
are: all adults diagnosed with asthma by a specialist, 
according to the GINA document, that are scheduled 
to visit a respiratory or allergy clinic. Patients involved 
in previous or concomitant observational studies can be 
enrolled. Patients that meet the inclusion criteria will 
receive an informative leaflet for themselves and their 
general practitioner and must provide written consent 
to participate in the study. Follow-ups will be scheduled 
according to the GINA document and each center’s plan.
The researchers will collect data on patient history, 
asthma features, comorbid diseases, and available spi-
rometry and imaging results. At the time of enroll-
ment, researchers will collect results from 
questionnaires. These data will include patient baseline 
characteristics, self-rated asthma control, and labora-
tory tests for allergy and airway inflammation. 
Follow-up data on asthma control, lung function, and 
environmental exposure will be collected by issuing 
questionnaires to participants at least every 
6–12 months to assess outcome and exacerbation-related 
aggravating factors. The information collected in the 
Case Report Form (CRF) will coincide with patient 
data routinely reported in medical records. The trans-
fer of data from the medical record to the analysis 
platform will be carried out by the physician that 
manages the therapy. Patients will be enrolled, starting 
in May 2021, and enrollment will continue until the 
established sample size is reached. Follow-up proce-
dures will last 10 years, starting from the date that 
the last patient is enrolled. The study was registered 
at ClinicalTrials.gov under the identifier NCT04796844.
An ad hoc CRF on the Web platform, REDCap, has 
been created. A similar database has been adopted by 
the Severe Asthma Network Italy (SANI), which is an 
ongoing project (16–24). Each center that participates 
in the MANI study will have a username and password, 
which allows access to a reserved area of the Web appli-
cation. Authentication is secure, with an https connec-
tion that encrypts the username and password. The 
passwords of each center are automatically stored in 
the database with MD5 coding. The web application is 
protected by Structured Query Language; therefore, it 
will not be possible to evade the authentication system 
or access data other than that which the application is 
allowed to return. For example, a given center will not 
be allowed, in any way, to display sensitive data from 
another center. Each patient registered in the database 
will be assigned a unique identification number, an 
identifiable code, which is used only by the physician 
providing therapy. The identification number is created 
by entering only the first three letters of the name, 
followed by the first three letters of the surname, the 
date of birth, the gender, and the province of residence, 
in the form of a cadastral code. Sensitive patient data 
can be viewed/edited only in the area reserved for  the 
center treating that patient. Each center will have the 
ability to view the clinical data of its own patients, but 
it will only be able to view the general descriptive sta-
tistics (e.g., the number of patients enrolled) of patients 
from the other centers that share the platform.
A statistical plan has been defined. Qualitative vari-
ables will be expressed as the absolute and relative 
frequencies (percentages), and quantitative variables 
will be expressed as the mean (standard deviation) 
or the median (interquartile range), based on the 
parametric or non-parametric distribution. The inci-
dence (and 95% confidence interval) of different forms 
of asthma will be calculated. Asthma severity will be 
defined according to the GINA document and a pre-
vious study (25). The role of demographic, clinical, 
and epidemiological variables in the evolution of 
asthma will be assessed with Cox proportional hazards 
regression analyses. All statistical analyses will be per-
formed with STATA version 16 statistical software 
(StataCorp, Texas, US). Based on a previous study 
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(1), we assume that at least 20,000 subjects should be 
enrolled to detect an estimated incidence of 8% for 
the primary outcome, with a beta error of 0.1 and 
an alpha error of 0.05.
Discussion
Because asthma is heterogeneous, we assume that each 
subject will exhibit a different subset of risk factors for 
asthma exacerbation and a different rate of disease 
progression. Therefore, this MANI study aims to iden-
tify mild/moderate asthma clusters, based on sociode-
mographic data, clinical data, and patient-reported 
outcomes. Additionally, the study results might suggest 
cluster-specific analytical strategies, by focusing on each 
subject’s individual aggravating factors during each 
exacerbation episode and by focusing on disease pro-
gression. We are aware that observational nature of the 
study and the recruitment in a secondary care in Italy 
will limit the generalizability of the results to different 
settings. However, we expect the cumulative results of 
the large number of patients would be helpful to 
improve the understanding of the epidemiological evo-
lution of mild and moderate asthma and provide new 
insights in the clinical management of such patients.
GINA 2020 provides a new approach for the man-
agement of mild asthma. However, as recently under-
lined by Boulet et  al. (26), despite recent advances in 
asthma care, several research gaps remain to be 
addressed through clinical research. Longitudinal, 
real-life studies will be exceptionally important for 
providing information on the translatability of clinical 
research results, the long-term efficacy of currently 
recommended strategies, and the ability to intervene 
in disease evolution.
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